Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor used to manage hyperglycemia in type 2 diabetes mellitus (DM). Also used to reduce the risk of major cardiovascular events in patients with established cardiovascular disease and type 2 DM. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 for a second indication of reducing the risk of cardiovascular events in patients diagnosed with type...
- Mechanism
- Curator reviewed
The sodium-glucose co-transporter2 (SGLT2), is found in the proximal tubules of the kidney, and reabsorbs filtered glucose from the renal tubular lumen. Canagliflozin inhibits the SGLT2 co-transporter. This inhibition leads to lower reabsorption of filtered glucose into the body and decreases the renal threshold for glucose (RTG), leading to increased glucose excretion in the urine.
- Primary indication
- This drug is used as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus.Curator reviewed · 12 structured indications
- Formula / weight
- C24H25FO5S · 444.516 g/mol (avg)
- First approval
- Canada, 2014 · United States, 2013 · European Union, 2020
- Brand names
Resolves to
XTNGUQKDFGDXSJ-ZXGKGEBGSA-NSMILES[H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C1=CC=C(C)C(CC2=CC=C(S2)C2=CC=C(F)C=C2)=C1What you can answer from here — as of September 23, 2026
Which drugs share a target with Canagliflozin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account